Table 3 Pre-treatment to 3-month follow-up observed mean and standard deviations for secondary outcomes
Variable | All patients (n = 122) | All Preference Trial patients (n = 74) | Preference Trial (n = 74) | Accepted for Self-Guided Only (n = 48) | Statisticala Significance χ2 or t-test | |
|---|---|---|---|---|---|---|
Guided (n = 60) | Self-Guided (n = 14) | Met Severity criteria but Out-of-Province (n = 48) | ||||
AUDIT | ||||||
Pretreatment | 22.65 (5.76) | 23.11 (6.19) | 24.07 (6.01) | 19.00 (5.39) | 21.94 (5.00) | p = .005 |
Posttreatment | 16.42 (8.09) | 18.00 (8.41) | 18.44 (8.89) | 15.86 (5.49) | 13.93 (6.97) | p = .48 |
Followup | 14.44 (7.59) | 14.80 (8.43) | 15.11 (8.69) | 13.38 (7.48) | 13.90 (6.22) | p = .60 |
PHQ-9 | ||||||
Pretreatment | 10.71 (5.71) | 11.35 (5.85) | 11.98 (5.69) | 8.64 (5.98) | 9.73 (5.39) | p = .05 |
Midtreatment | 6.76 (5.09) | 6.75 (5.13) | 6.74 (4.61) | 6.80 (7.67) | 6.78 (5.08) | p = .97 |
Posttreatment | 6.13 (5.35) | 6.25 (5.54) | 6.50 (5.53) | 4.89 (5.73) | 5.94 (5.12) | p = .43 |
Followup | 5.55 (4.73) | 5.89 (4.79) | 5.67 (4.73) | 6.88 (5.22) | 5.03 (4.69) | p = .53 |
GAD-7 | ||||||
Pretreatment | 8.90 (5.45) | 9.27 (5.52) | 10.08 (5.36) | 5.79 (4.95) | 8.33 (5.35) | p = .008 |
Posttreatment | 4.93 (4.44) | 5.28 (4.37) | 5.55 (4.70) | 4.00 (1.85) | 4.40 (4.57) | p = .37 |
Followup | 4.84 (4.48) | 4.84 (3.86) | 5.06 (4.06) | 3.88 (2.75) | 4.83 (5.37) | p = .44 |
PACS | ||||||
Pretreatment | 17.02 (5.95) | 17.24 (6.12) | 17.60 (6.06) | 15.71 (6.37) | 16.69 (5.72) | p = .30 |
Posttreatment | 12.27 (6.43) | 12.76 (5.80) | 12.95 (6.12) | 11.86 (4.09) | 11.53 (7.33) | p = .64 |
Followup | 10.67 (5.91) | 11.25 (6.28) | 10.67 (5.88) | 13.88 (7.72) | 9.79 (5.28) | p = .20 |
CEQ | ||||||
Midtreatment | 22.18 (4.02) | 22.10 (4.19) | 22.32 (4.02) | 20.90 (5.09) | 22.33 (3.75) | p = .33 |